Loading stock data…
$0.81-0.05 (-5.81%)
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
CytoMed Therapeutics Limited in the Healthcare sector is trading at $0.81 with a market capitalization of $14M. Wall Street consensus targets $4.16 (1 analysts), implying a +413.6% move over the next 12 months. The stock is currently near its 52-week low of $0.68, remaining 19.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidat...